Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in
combination with pembrolizumab in subjects with solid tumor malignancies. The study will
include a safety lead-in portion followed by a phase 2 expansion portion in specific disease
groups.